Pan, 762 patient aspirin prophylaxis study: 13% higher mortality [p=0.63] and 2% higher combined mortality/intubation [p=0.93] https://c19p.org/pan
copied to clipboard
Pre-hospital antiplatelet medication use on COVID-19 disease severity
et al., Heart & Lung, doi:10.1016/j.hrtlng.2021.04.010
Retrospective 762 COVID+ hospitalized patients in the USA, 239 on antiplatelet medication (199 aspirin), showing no significant differences in outcomes.For more discussion see [sciencedirect.com].
|
risk of death, 13.0% higher, OR 1.13, p = 0.63, treatment 239, control 523, adjusted per study, MOS 6 vs. <6, multivariable, RR approximated with OR.
|
|
risk of death/intubation, 2.0% higher, OR 1.02, p = 0.93, treatment 239, control 523, adjusted per study, MOS 5+ vs. <5, multivariable, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Pan et al., 26 May 2021, retrospective, USA, peer-reviewed, 11 authors, study period 1 March, 2020 - 9 April, 2020.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.